The application discloses an organic compound, an electronic element with the organic compound, and an electronic device including the electronic element. The organic compound of the present application has a fused heteroaromatic group containing fluorenyl or silylfluorenyl as its core structure, which presents a large planar structure in a three-dimensional (3D) space; and an electron-rich arylamine or heteroarylamine substituent is introduced at position 9 of the fluorenyl or silylfluorenyl to make the compound have excellent hole transport performance.

The present disclosure relates to an organic compound. The organic compound has a structure as shown in the following formula (1), where R.sub.1 and R.sub.2 are the same as or different from each other, and are each independently substituted or unsubstituted alkyl with 1 to 4 carbon atoms, or substituted or unsubstituted phenyl; each Y is the same or different, and independently has a structure as shown in a formula (2); X.sub.1, X.sub.2, X.sub.3, X.sub.4, and X.sub.5 are the same or different, and are each independently C(R.sub.4) or N, and at least one of X.sub.1, X.sub.2, X.sub.3, X.sub.4, and X.sub.5 is N; m is selected from 1 or 2; and n is selected from 1 or 2. The organic compound of the present disclosure may be used as a hole blocking layer and/or an electron transport layer of an organic electroluminescent device.

##STR00001##

The present disclosure relates to an organic compound. The organic compound has a structure as shown in the following formula (1), where R.sub.1 and R.sub.2 are the same as or different from each other, and are each independently substituted or unsubstituted alkyl with 1 to 4 carbon atoms, or substituted or unsubstituted phenyl; each Y is the same or different, and independently has a structure as shown in a formula (2); X.sub.1, X.sub.2, X.sub.3, X.sub.4, and X.sub.5 are the same or different, and are each independently C(R.sub.4) or N, and at least one of X.sub.1, X.sub.2, X.sub.3, X.sub.4, and X.sub.5 is N; m is selected from 1 or 2; and n is selected from 1 or 2. The organic compound of the present disclosure may be used as a hole blocking layer and/or an electron transport layer of an organic electroluminescent device.

##STR00001##

The present technology is directed to compounds, compositions, and methods related to non-morphinan-like mu opioid receptor agonists. Compounds of the present technology demonstrate remarkable potency and selectivity for the mu opioid receptor over the kappa opioid receptor, while also exhibiting a significant reduction (or, essentially, absence) of the negative side effects of many morphine-derived compounds.

The present technology is directed to compounds, compositions, and methods related to non-morphinan-like mu opioid receptor agonists. Compounds of the present technology demonstrate remarkable potency and selectivity for the mu opioid receptor over the kappa opioid receptor, while also exhibiting a significant reduction (or, essentially, absence) of the negative side effects of many morphine-derived compounds.

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula (I) are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.

##STR00001##

Compounds useful for affinity chromatography as presented, more particularly for use in affinity chromatography to purify serum albumin, especially human serum albumin (HSA) and fusion proteins thereof. Methods for extending the half-life of therapeutic agents are also presented, particularly therapeutic peptide agents and small molecules, such as by conjugation of compounds described herein to the therapeutic peptide or small molecule, which upon administration, binds to HSA, thereby providing a prolonged release of the therapeutic agent.

Compounds useful for affinity chromatography as presented, more particularly for use in affinity chromatography to purify serum albumin, especially human serum albumin (HSA) and fusion proteins thereof. Methods for extending the half-life of therapeutic agents are also presented, particularly therapeutic peptide agents and small molecules, such as by conjugation of compounds described herein to the therapeutic peptide or small molecule, which upon administration, binds to HSA, thereby providing a prolonged release of the therapeutic agent.

The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

##STR00001##

An electrolytic solution includes the compound of Formula I and a carboxylate compound:

##STR00001##

The electrochemical device prepared with the electrolytic solution has reduced storage impedance, and improved post-storage swelling, overcharge performance and hot box performance.